AML Practical Tips
Practical Tips for Navigating the Complex Landscape of AML Care

Released: October 13, 2023

Courtney DiNardo
Courtney DiNardo, MD, MSCE
Natasha L. Johnson
Natasha L. Johnson, MSN, APRN, AOCNP

Activity

Progress
1
Course Completed

Here is our list of key points to remember when caring for your patients diagnosed with acute myeloid leukemia (AML) from our recent presentation “Meeting the Many Challenges of Current AML Care: Case Discussion and Practical Strategies.

  • Genetic testing should be performed for all patients with newly diagnosed AML to guide treatment decisions.
    • IDH1 or FLT3 mutations are actionable in the first-line setting, and IDH2 mutations are actionable in relapsed/refractory disease.
    • Retesting at relapse is crucial to detect clonal evolution.
  • Patients with newly diagnosed AML who are eligible for intensive chemotherapy may be treated with CPX-351 as an alternative to a 7+3 regimen and may benefit from maintenance therapy with oral azacitidine.
  • Patients with newly diagnosed AML who are unfit for intensive chemotherapy may consider azacitidine plus venetoclax.
    • Initial dose ramp-up and dose reductions of venetoclax as needed during the course of treatment may help optimize tolerability.
  • Proactive communication and agent-specific adverse event monitoring can maximize treatment adherence and allow patients to experience optimal therapeutic benefits

Your Thoughts?
What questions do you have about the evolving landscape of AML therapies? What are the primary concerns of your patients with AML, and how do you address them? Leave a comment below and join the discussion.

Poll

1.

How often do you consider increased monitoring or reduced starting doses for patients who are starting venetoclax therapy and have risk factors for tumor lysis syndrome?

Submit